Cargando…

Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma

With the growing knowledge of multiple myeloma (MM) pathobiology and the introduction of novel therapies, risk stratification continues to evolve. Myeloid-derived suppressor cells and tumor-associated macrophages, derived from peripheral blood monocytes, support malignant plasma cell proliferation i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edwards, Camille V., Hassan, Hamza, Yildirim, Cenk, Ferri, Grace, Verma, Karina P., Murray Horwitz, Mara E., Fillmore, Nathanael R., Munshi, Nikhil C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979755/ https://www.ncbi.nlm.nih.gov/pubmed/36409606 http://dx.doi.org/10.1182/bloodadvances.2022008021

Ejemplares similares

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
por: Yao, Yao, et al.
Publicado: (2023)

Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma
por: Merz, Maximilian, et al.
Publicado: (2022)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
por: Chari, Ajai, et al.
Publicado: (2020)

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
por: Yan, Yuting, et al.
Publicado: (2022)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

Outcomes after biochemical or clinical progression in patients with multiple myeloma
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma
por: Barnell, Erica K., et al.
Publicado: (2022)

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
por: Charalampous, Charalampos, et al.
Publicado: (2023)

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023)

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Linked-read whole-genome sequencing resolves common and private structural variants in multiple myeloma
por: Peña-Pérez, Lucía, et al.
Publicado: (2022)

Extracellular vesicle proteomic analysis leads to the discovery of HDGF as a new factor in multiple myeloma biology
por: Hoelzinger, Dominique B., et al.
Publicado: (2022)

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
por: Gooding, Sarah, et al.
Publicado: (2022)

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2021)

The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network
por: Hapgood, Greg, et al.
Publicado: (2023)

Uptake of long-chain fatty acids from the bone marrow suppresses CD8(+) T-cell metabolism and function in multiple myeloma
por: Gudgeon, Nancy, et al.
Publicado: (2023)

Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma
por: Brownlie, Rebecca J., et al.
Publicado: (2023)

Junctional adhesion molecule C expression specifies a CD138(low/neg) multiple myeloma cell population in mice and humans
por: Brandl, Andreas, et al.
Publicado: (2022)

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
por: Johnson, William T., et al.
Publicado: (2023)

Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers
por: Rodríguez, Marta, et al.
Publicado: (2021)

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
por: Bowers, Jackson T., et al.
Publicado: (2023)

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma
por: Vanden Bempt, Marlies, et al.
Publicado: (2022)

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data
por: Horwitz, Steven M., et al.
Publicado: (2021)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022)

Retrospective characterization of nodal marginal zone lymphoma
por: Stuver, Robert, et al.
Publicado: (2023)

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
por: Hamadani, Mehdi, et al.
Publicado: (2022)

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
por: Gouni, Sushanth, et al.
Publicado: (2022)

Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL
por: Passet, Marie, et al.
Publicado: (2022)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001
por: Tran, Thai Hoa, et al.
Publicado: (2022)

Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia
por: Li, Zhenhua, et al.
Publicado: (2021)

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
por: Haydu, J. Erika, et al.
Publicado: (2022)

SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma
por: Wrench, David, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qnlsqdep5flsk8412h7i6g8lmk